ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 31

Patients with Either Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA) Self-Reported Flares in 24% of Assessments: An Observational Study of 86 Patients Assessed Weekly over 3 Months (ie, 1,100 assessments)

Charlotte Jacquemin1, Herve Servy2, Anna Molto3, Jeremie Sellam4, Violaine Foltz1, Frédérique Gandjbakhch1, Christophe Hudry3, Stéphane Mitrovic1, Bruno Fautrel1 and Laure Gossec1, 1Rheumatology, Pitié Salpêtrière Hospital, Paris, France, 2Sanoia, La Ciotat, France, 3Rheumatology, Cochin Hospital, Paris, France, 4Rheumatology, Saint-Antoine Hospital, Paris, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: axial spondyloarthritis and rheumatoid arthritis (RA), Disease Activity

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Epidemiology and Public Health - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  The evolution of RA and axSpA is characterized by alternated periods of flares and remission. This fluctuating disease activity can be self-assessed by a single question [1]. The objective was to assess the frequency of flares when assessed weekly and the link between flares and well-validated patient reported outcomes (PROs).

Methods: In this prospective longitudinal multicenter observational study aiming to explore physical activity and its relation with disease activity. Patients had definite axSpA (ASAS criteria) or RA (ACR/EULAR criteria). Patients were asked to complete every week during 3 months different PROs including pain and patient global assessment (PGA) and flare status. Flares were recorded using the question (« has your disease flared up during the last 7 days ? ») [1], with a categorical response: no flare, flare lasting 1 to 3 days or flare lasting more than 3 days. Flare frequency was calculated by the number of reported flares divided by the number of completed questionnaires over the 3 months. The frequency of flares in RA and axSpA patients was compared by Mann-Whitney test. Pain and PGA were compared across assessments according to flare status using ANOVA on repeated measures (linear mixed-effects model).

Results:  86 patients (45 RA and 41 axSpA patients) were included in this analysis: 37 (43.0%) were males, with a mean age of 46.3 (±11.7) and a mean disease duration of 10.8 (±7.9) years, 48 (55.8%) were receiving a biologic. RA and axSpA patients had respectively a mean DAS 28 of 2.2 (±1.0) and a mean BASDAI of 3.5 (±2.1). Patients reported flares on average in 23.9% (±23.1) of the weekly questionnaires, with a mean frequency of ‘1 to 3 days flares’ and ‘>3 days flares’ respectively of 17.2% (±17.0) and 6.7% (±14.1). Flare frequency and duration of flares were higher in RA than axSpA, in particular for short flares, though this difference did not reach statistical significance (Table 1). Pain and PGA were higher when patients self-reported flares and in particular longer flares rather than “bad days” (Table 2). Table 1: Mean frequency of flares per patient according to their duration in RA and axSpA patients

All patients (n=83) RA (n=45) axSpA (n=41) p
Frequency of all flares, mean (SD) 23.9 (±23.1) 27.0 (±24.5) 20.5 (±21.3) 0.20
Frequency of 1-3 days flares, mean (SD) 17.2 (±17.0) 20.4 (±19.5) 13.8 (±13.1) 0.16
Frequency of >3 days flares, mean (SD) 6.7 (±14.1) 6.6 (±10.9) 6.8 (±17.1) 0.31

Table 2: PROs according to flare status

No flare (n=836 questionnaires)

1-3 days flares (n=191 questionnaires)

>3 days flares (n=73 questionnaires)

P
Pain 0-10, mean (SD) 2.2 (±1.8) 4.4 (±1.7) 6.5 (±2.0) <0.0001
PGA 0-10, mean (SD) 2.3 (±1.9) 4.4 (±1.8) 6.4 (±2.3) <0.0001

Conclusion:  self-reported flares were frequent in RA and axSpA, in this population of long-standing disease with good inflammation control. Long flares (>3 days) were less frequent. Self-reported flares were substantiated by higher PROs. More work is needed on long-term effects of flares. 1. VP Byberk et al, RMD Open, 2016; 2(1):e000225.


Disclosure: C. Jacquemin, None; H. Servy, None; A. Molto, None; J. Sellam, None; V. Foltz, None; F. Gandjbakhch, None; C. Hudry, None; S. Mitrovic, None; B. Fautrel, None; L. Gossec, None.

To cite this abstract in AMA style:

Jacquemin C, Servy H, Molto A, Sellam J, Foltz V, Gandjbakhch F, Hudry C, Mitrovic S, Fautrel B, Gossec L. Patients with Either Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA) Self-Reported Flares in 24% of Assessments: An Observational Study of 86 Patients Assessed Weekly over 3 Months (ie, 1,100 assessments) [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/patients-with-either-rheumatoid-arthritis-ra-or-axial-spondyloarthritis-axspa-self-reported-flares-in-24-of-assessments-an-observational-study-of-86-patients-assessed-weekly-over-3-months-ie-1/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-with-either-rheumatoid-arthritis-ra-or-axial-spondyloarthritis-axspa-self-reported-flares-in-24-of-assessments-an-observational-study-of-86-patients-assessed-weekly-over-3-months-ie-1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology